MMP2 and ovarian serous carcinoma: Even though the TCGA datasets from three studies on 1680 serous ovarian carcinomas suggests a prognostic utility (OS and PFS) of MMP-14 based on its altered and unaltered genetic expression in serous ovarian cancer patients, no such links could be made with TIMP-1, -3 or MMP-2, -9, and -11.